Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents

Xiangshu Fei, Qi Huang Zheng, Gary D. Hutchins, Xuan Liu, K. Lee Stone, Kathy A. Carlson, Bruce H. Mock, Wendy L. Winkle, Barbara E. Glick-Wilson, Kathy D. Miller, Rose S. Fife, George W. Sledge, Hui Bin Sun, Raymond E. Carr

Research output: Contribution to journalArticle

37 Scopus citations


[11C]Methyl-CGS 27023A (1a) and its analogs [11C]methyl-2-picolyl-CGS 27023A (1b), [11C]methyl-benzyl-CGS 27023A (1c), [11C]methyl-2-nitro-CGS 27023A (1d), [11C]methyl-3-nitro-CGS 27023A (1e), and [11C]methyl-4-nitro-CGS 27023A (1f), novel radiolabeled matrix metalloproteinase (MMP) inhibitors, have been synthesized for evaluation as new potential positron emission tomography (PET) breast cancer imaging agents. The appropriate precursors for radiolabeling were obtained in four to five steps from starting material amino acid D-valine with moderate to excellent chemical yields. Precursors were labeled by [11C]methyl triflate through 11C-O-methylation method at the aminohydroxyl position under basic conditions and isolated by solid-phase extraction (SPE) purification to produce pure target compounds in 40-60% radiochemical yields (decay corrected to end of bombardment), in 20-25 min synthesis time.

Original languageEnglish (US)
Pages (from-to)449-470
Number of pages22
JournalJournal of Labelled Compounds and Radiopharmaceuticals
Issue number6
StatePublished - Jun 13 2002



  • [C]methyl-CGS 27023A
  • Breast cancer
  • Carbon-11
  • Matrix metalloproteinase inhibitor
  • Positron emission tomography
  • Radiotracer

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Organic Chemistry
  • Clinical Biochemistry
  • Molecular Medicine
  • Pharmacology

Cite this